BR112019018277A2 - aparelho e método para avaliar e tratar celulite - Google Patents
aparelho e método para avaliar e tratar celulite Download PDFInfo
- Publication number
- BR112019018277A2 BR112019018277A2 BR112019018277-2A BR112019018277A BR112019018277A2 BR 112019018277 A2 BR112019018277 A2 BR 112019018277A2 BR 112019018277 A BR112019018277 A BR 112019018277A BR 112019018277 A2 BR112019018277 A2 BR 112019018277A2
- Authority
- BR
- Brazil
- Prior art keywords
- cellulite
- pcss
- severity
- scale
- fact
- Prior art date
Links
- 208000035484 Cellulite Diseases 0.000 title claims abstract description 266
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 266
- 230000036232 cellulite Effects 0.000 title claims abstract description 266
- 238000000034 method Methods 0.000 title claims abstract description 86
- 210000001217 buttock Anatomy 0.000 claims abstract description 200
- 210000000689 upper leg Anatomy 0.000 claims abstract description 137
- 238000011282 treatment Methods 0.000 claims description 152
- 230000006872 improvement Effects 0.000 claims description 90
- 238000002347 injection Methods 0.000 claims description 80
- 239000007924 injection Substances 0.000 claims description 80
- 108060005980 Collagenase Proteins 0.000 claims description 27
- 102000029816 Collagenase Human genes 0.000 claims description 27
- 229960002424 collagenase Drugs 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 18
- 238000011156 evaluation Methods 0.000 claims description 17
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 241000193159 Hathewaya histolytica Species 0.000 claims description 5
- 238000002203 pretreatment Methods 0.000 claims description 5
- 101150014058 MMP1 gene Proteins 0.000 claims description 3
- 108700004333 collagenase 1 Proteins 0.000 claims description 3
- 238000012800 visualization Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 description 67
- 108010013295 Microbial collagenase Proteins 0.000 description 55
- 229960005099 collagenase clostridium histolyticum Drugs 0.000 description 55
- 239000000902 placebo Substances 0.000 description 43
- 229940068196 placebo Drugs 0.000 description 43
- 238000010988 intraclass correlation coefficient Methods 0.000 description 33
- 210000003491 skin Anatomy 0.000 description 29
- 210000002370 ICC Anatomy 0.000 description 20
- 230000008859 change Effects 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 230000008569 process Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000013102 re-test Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 238000010200 validation analysis Methods 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000000877 morphologic effect Effects 0.000 description 6
- 238000007665 sagging Methods 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 238000012562 intraclass correlation Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000004362 Penile Induration Diseases 0.000 description 3
- 208000020758 Peyronie disease Diseases 0.000 description 3
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000002497 edematous effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 238000011240 pooled analysis Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005315 distribution function Methods 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000002647 laser therapy Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000007443 liposuction Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940127554 medical product Drugs 0.000 description 2
- 238000000694 mesotherapy Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000001708 Dupuytren contracture Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010070653 Penile curvature Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- HJJVPARKXDDIQD-UHFFFAOYSA-N bromuconazole Chemical compound ClC1=CC(Cl)=CC=C1C1(CN2N=CN=C2)OCC(Br)C1 HJJVPARKXDDIQD-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000002078 massotherapy Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000036410 touch Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 108010012672 xiapex Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24003—Microbial collagenase (3.4.24.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/107—Measuring physical dimensions, e.g. size of the entire body or parts thereof
- A61B5/1079—Measuring physical dimensions, e.g. size of the entire body or parts thereof using optical or photographic means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Zoology (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465622P | 2017-03-01 | 2017-03-01 | |
| US62/465,622 | 2017-03-01 | ||
| US201762485705P | 2017-04-14 | 2017-04-14 | |
| US62/485,705 | 2017-04-14 | ||
| US201762607188P | 2017-12-18 | 2017-12-18 | |
| US62/607,188 | 2017-12-18 | ||
| PCT/US2018/020551 WO2018160905A1 (en) | 2017-03-01 | 2018-03-01 | Apparatus and method for assessing and treating cellulite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019018277A2 true BR112019018277A2 (pt) | 2020-06-30 |
Family
ID=61768443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019018277-2A BR112019018277A2 (pt) | 2017-03-01 | 2018-03-01 | aparelho e método para avaliar e tratar celulite |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US11123280B2 (enExample) |
| EP (2) | EP4591945A2 (enExample) |
| JP (2) | JP7558654B2 (enExample) |
| KR (3) | KR20230003601A (enExample) |
| CN (2) | CN110545722B (enExample) |
| AU (4) | AU2018226820B2 (enExample) |
| BR (1) | BR112019018277A2 (enExample) |
| CA (1) | CA3055041A1 (enExample) |
| DK (1) | DK3589204T3 (enExample) |
| ES (1) | ES3036011T3 (enExample) |
| FI (1) | FI3589204T3 (enExample) |
| HU (1) | HUE072115T2 (enExample) |
| IL (2) | IL301796A (enExample) |
| MX (2) | MX2023008072A (enExample) |
| NZ (1) | NZ756787A (enExample) |
| PL (1) | PL3589204T3 (enExample) |
| PT (1) | PT3589204T (enExample) |
| WO (1) | WO2018160905A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2861033C (en) | 2012-01-12 | 2017-07-25 | Auxilium International Holdings, Inc. | Clostridium histolyticum enzymes and methods for the use thereof |
| KR20230003601A (ko) | 2017-03-01 | 2023-01-06 | 엔도 벤쳐즈 리미티드 | 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법 |
| CN118325876A (zh) | 2017-03-28 | 2024-07-12 | 恩多风投有限公司 | 生产胶原酶的改进方法 |
| WO2020021332A2 (en) | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
| WO2020021330A2 (en) | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
| KR20210079291A (ko) | 2018-09-18 | 2021-06-29 | 엔도 글로벌 에스테틱스 리미티드 | 셀룰라이트를 치료하기 위한 조성물 및 방법 |
| US20220305094A1 (en) | 2019-01-06 | 2022-09-29 | Endo Global Aesthetics Limited | Collagenase formulations and methods of producing the same |
| US11432733B2 (en) | 2019-03-13 | 2022-09-06 | Blossom Innovations | Tissue detection devices, systems and methods |
| IL311679A (en) | 2019-03-13 | 2024-05-01 | Blossom Innovations Llc | Devices, systems and methods for tissue analysis, positioning and treatments using optical radiation. |
| US20220095925A1 (en) | 2019-03-13 | 2022-03-31 | Blossom Innovations, LLC | Devices, systems and methods for tissue analysis, location determination and therapy thereof using optical radiation |
| CN113033528A (zh) * | 2021-05-27 | 2021-06-25 | 明品云(北京)数据科技有限公司 | 一种反馈量表评估方法、系统、设备和介质 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3821364A (en) | 1966-07-08 | 1974-06-28 | Advance Biofactures Corp | Process of producing collagenase |
| JPS5662229A (en) | 1979-10-25 | 1981-05-28 | Asahi Glass Co Ltd | Electro-optical dimming panel |
| US4338300A (en) | 1981-02-05 | 1982-07-06 | The Regents Of The University Of California | Use of purified clostridial collangenase in the treatment of Peyronie's disease |
| WO1984002653A1 (fr) | 1983-01-05 | 1984-07-19 | Pasteur Institut | Preparation a activite collagenolytique ayant une activite elevee et compositions pharmaceutiques la contenant |
| US4524065A (en) | 1983-08-04 | 1985-06-18 | Bio-Specifics N.V. | Method for the prevention and treatment of scars with enzymes |
| US4645668A (en) | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
| US5252461A (en) | 1990-05-01 | 1993-10-12 | The Regents Of The Univ. Of California | Mixed immunoglobulins for detection of rheumatoid factors |
| CA2047306A1 (en) | 1990-07-23 | 1992-01-24 | Milan Holjevac | Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase |
| US5393792A (en) | 1991-11-20 | 1995-02-28 | Advance Biofactures Of Curacao, N.V. | High dosage topical forms of collagenase |
| US5462739A (en) | 1991-11-21 | 1995-10-31 | Yeda Research And Development Co., Ltd. | Microdelivery device and method for enhanced drug administration to the eye |
| US5256140A (en) | 1992-03-27 | 1993-10-26 | Fallien Cosmeceuticals, Ltd. | Composition for levelling skin |
| CA2138948A1 (en) | 1992-06-22 | 1994-01-06 | Hun-Chi Lin | Molecular cloning of the genes responsible for collagenase production from clostridium histolyticum |
| JP3186881B2 (ja) | 1993-02-18 | 2001-07-11 | 倉敷紡績株式会社 | 肝細胞の分離方法 |
| US5332503A (en) | 1993-04-16 | 1994-07-26 | Baxter International Inc. | Process for purifying collagenase |
| US5514340A (en) | 1994-01-24 | 1996-05-07 | Magnetix Biotechnology, Inc. | Device for separating magnetically labelled cells |
| JP3028852B2 (ja) | 1994-06-24 | 2000-04-04 | ロシュ ダイアグノスティックス コーポレーション | ヒストリチクス菌から得られるコラゲナーゼおよび２つの他のプロテアーゼの精製混合物 |
| US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
| CA2158822C (en) | 1994-09-27 | 2008-12-23 | Kusuki Nishioka | Therapeutic agent for rheumatic disease |
| US6958150B2 (en) | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
| PL322271A1 (en) | 1995-03-16 | 1998-01-19 | Knoll Ag | Novel defined mixtures of enzymes for use in growing cells and healing wounds |
| IT1279011B1 (it) | 1995-06-15 | 1997-12-02 | Ips Int Prod Services | Apparecchiatura per la rilevazione e scelta dei trattamenti della cellulite |
| US5705170A (en) * | 1995-10-24 | 1998-01-06 | Plantech International, Inc. | Herbal cellulite treatments |
| US5989888A (en) | 1996-01-24 | 1999-11-23 | Roche Diagnostics Corporation | Purified mixture of collagenase I, collagenase II and two other proteases |
| WO1998022574A2 (de) | 1996-11-19 | 1998-05-28 | Roche Diagnostics Gmbh | Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden |
| US5830741A (en) | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
| US5753785A (en) | 1996-12-16 | 1998-05-19 | Fina Technology, Inc. | Production of E-B copolymers with a single metallocene catalyst and a single monomer |
| US6086872A (en) | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
| JPH10262658A (ja) | 1997-03-28 | 1998-10-06 | Kikkoman Corp | ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造 |
| TR200001789T2 (tr) | 1997-10-03 | 2000-10-23 | Lavipharm Laboratories, Inc. | Prolamin-bitki kutuplu lipit kompozisyonu, bunun hazırlama ve uygulama metodu |
| GB9724802D0 (en) | 1997-11-24 | 1998-01-21 | Unilever Plc | Antiperspirant or deodorant compoistions |
| US20020036328A1 (en) | 1998-11-16 | 2002-03-28 | William R. Richards, Jr. | Offset drain fermi-threshold field effect transistors |
| FR2788682B1 (fr) * | 1999-01-26 | 2001-04-06 | Seb Sa | Dispositif de thermographie |
| US6022539A (en) | 1999-06-03 | 2000-02-08 | Advance Biofactures Of Curacao | Amelioration of peyronie's disease |
| RU2180002C2 (ru) | 1999-08-16 | 2002-02-27 | Пермское научно-производственное объединение "Биомед" | Способ получения коллагеназы |
| US6358539B1 (en) | 1999-08-20 | 2002-03-19 | Howard Murad | Pharmaceutical compositions for reducing the appearance of cellulite |
| US6280993B1 (en) | 1999-08-24 | 2001-08-28 | Ichiro Yamato | Gene encoding class I collagenase |
| ITMI991894A1 (it) * | 1999-09-09 | 2001-03-09 | Carlo Ghisalberti | Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso |
| DK1220830T3 (da) | 1999-09-24 | 2007-07-16 | Proteon Therapeutics Inc | Anvendelse af elastase til åbning af obstruerede arterier og vener |
| EP1187602A4 (en) | 2000-04-18 | 2004-09-15 | Peptron Inc | SUSTAINABLE RELEASE INJECTABLE PHARMACEUTICAL COMPOSITION AND METHODS OF PREPARING THE SAME |
| EP1355566B1 (en) | 2000-12-18 | 2012-11-28 | Board Of Regents, The University Of Texas System | Local regional chemotherapy and radiotherapy using in situ hydrogel |
| WO2002060410A2 (en) | 2001-01-30 | 2002-08-08 | The Regents Of The University Of Michigan | Methods for sustained release local delivery of drugs for ablation of unwanted tissue |
| ATE302844T1 (de) | 2001-07-02 | 2005-09-15 | Nordmark Arzneimittel Gmbh & C | Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms |
| GB0124124D0 (en) | 2001-10-08 | 2001-11-28 | Medical Res Council | Methods of treatment |
| ES2300569T3 (es) * | 2002-03-15 | 2008-06-16 | The General Hospital Corporation | Dispositivos para la perturbacion selectiva de tejido graso mediante enfriamiento controlado. |
| JP2003284553A (ja) | 2002-03-28 | 2003-10-07 | Seikagaku Kogyo Co Ltd | 生理活性タンパク質 |
| EP1538980B1 (en) * | 2002-06-25 | 2017-01-18 | Ultrashape Ltd. | Device for body aesthetics |
| EP1433845A1 (en) | 2002-12-23 | 2004-06-30 | Georg-August-Universität | Clostridium tetani collagenase and uses thereof |
| EP1462519A1 (en) | 2003-03-24 | 2004-09-29 | Boehringer Ingelheim Austria GmbH | Method and devices for producing biomolecules |
| JP4205496B2 (ja) | 2003-06-19 | 2009-01-07 | 三菱化学株式会社 | 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法 |
| NZ576986A (en) | 2004-01-30 | 2010-12-24 | Shire Pharmaceuticals Ireland Ltd | Production and purification of recombinant arylsulfatase A |
| US8147428B2 (en) * | 2004-04-16 | 2012-04-03 | University Of Massachusetts | Device and method for quantifying edema |
| SI2422789T1 (en) | 2004-05-19 | 2018-07-31 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Injectable coposition comprising sodium deoxycholate |
| US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
| US7355027B2 (en) | 2004-06-16 | 2008-04-08 | Dynport Vaccine Company Llc | Bacillus anthracis protective antigen |
| SI1781697T1 (sl) | 2004-07-07 | 2009-08-31 | Lundbeck & Co As H | Novi karbamilirani epo in postopek za njegovo izdelavo |
| EP1773400A2 (en) | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutic peptides |
| CN101010274B (zh) | 2004-08-30 | 2012-09-05 | 大赛璐化学工业株式会社 | 聚甘油单醚及其制造方法 |
| US20150025420A1 (en) * | 2004-10-06 | 2015-01-22 | Guided Therapy Systems, Llc | Ultrasound treatment device and methods of use |
| DE102004060075A1 (de) | 2004-12-14 | 2006-07-06 | Merck Patent Gmbh | Verfahren zur Herstellung von Onium-Salzen mit Dialkylphosphat-, Dialkylphosphinat oder (O-Alkyl)-alkyl- oder Alkyl-phosphonat-Anionen mit geringem Halogenid-Gehalt |
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| KR20090130158A (ko) | 2005-01-21 | 2009-12-17 | 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 | 유착 관절낭염을 치료하는 방법 |
| US7854929B2 (en) | 2005-01-21 | 2010-12-21 | The Research Foundation Of State University Of New York | Method for treating lateral epicondylitis using collagenase |
| JP2006254876A (ja) | 2005-03-18 | 2006-09-28 | Hokkaido Univ | Ｌ−トリプトファン製造法 |
| US20060251581A1 (en) | 2005-05-09 | 2006-11-09 | Mcintyre Jon T | Method for treatment of uterine fibroid tumors |
| US20070003541A1 (en) | 2005-07-01 | 2007-01-04 | Rodolfo Faudoa | Methods and compositions for therapeutics |
| ITPD20050207A1 (it) | 2005-07-07 | 2007-01-08 | Fidia Farmaceutici | Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere |
| US20070031482A1 (en) * | 2005-08-02 | 2007-02-08 | Ceramoptec Industries, Ind. | PDT treatment method for cellulites and cosmetic use |
| JP3122177U (ja) * | 2005-09-28 | 2006-06-08 | 株式会社資生堂 | セルライトの診断基準シート |
| US7811560B2 (en) | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| WO2007100590A2 (en) * | 2006-02-22 | 2007-09-07 | Auxilium Pharmaceuticals, Inc. | Methods for treating cellulite |
| US20100015262A1 (en) * | 2006-03-31 | 2010-01-21 | Regina Goralczyk | Novel use of compounds and combinations of compounds for improving the physical appearance |
| WO2008100833A2 (en) | 2007-02-13 | 2008-08-21 | Auxilium International Holdings, Inc. | Production of recombinant collagenases colg and colh in escherichia coli |
| US8617543B2 (en) | 2007-02-14 | 2013-12-31 | Yolare Pharmaceuticals, LLC | Modified mutant collagenase and its use in fat melting and in scar reduction |
| MX2009012042A (es) * | 2007-05-11 | 2009-12-01 | Sigma Tau Ind Farmaceuti | Gel util para el suministro de ingredientes activos cosmeticos. |
| US9987221B2 (en) | 2007-08-23 | 2018-06-05 | Boston Scientific Scimed, Inc. | Injectable hydrogel compositions |
| WO2009059379A1 (en) | 2007-11-07 | 2009-05-14 | Dynamic Microbials Limited | Antimicrobial compositions, formulations and uses thereof |
| US20100159564A1 (en) | 2007-11-30 | 2010-06-24 | Dwulet Francis E | Protease resistant recombinant bacterial collagenases |
| ES2388219T3 (es) | 2008-06-02 | 2012-10-10 | F. Hoffmann-La Roche Ag | Purificación mejorada de colagenasas a partir de un cultivo líquido de Clostridium histolyticum |
| US8236356B2 (en) | 2008-06-11 | 2012-08-07 | Roche Diagnostics Operations, Inc. | Growth medium for Clostridium histolyticum |
| JP5421366B2 (ja) | 2008-07-21 | 2014-02-19 | オトノミ―，インク． | 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法 |
| US8380531B2 (en) | 2008-07-25 | 2013-02-19 | Invivodata, Inc. | Clinical trial endpoint development process |
| EP2369956A1 (en) | 2008-10-22 | 2011-10-05 | Allergan, Inc. | Clinical assessment scales and methods |
| AU2009315771A1 (en) * | 2008-11-11 | 2010-05-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Compound useful for treating cellulite |
| EP2363461B1 (en) | 2008-11-19 | 2014-12-24 | Meiji Seika Pharma Co., Ltd. | Fusion collagenase to which affinity tag is attached, and method for producing same |
| IT1397646B1 (it) | 2009-12-15 | 2013-01-18 | Seidita | Collagenasi ricombinanti di c. histolyticum e metodo per la loro produzione. |
| US9132199B2 (en) | 2010-03-05 | 2015-09-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Reverse thermal gels and uses therefor |
| WO2011130537A2 (en) | 2010-04-14 | 2011-10-20 | Northwestern University | Pharmaceutical compositions and methods for digesting atherosclerotic plaques |
| EP2605702A4 (en) * | 2010-08-19 | 2014-09-17 | Medicis Pharmaceutical Corp | FACIAL SYSTEM AESTHETIC SCALING SYSTEM AND CORRESPONDING METHOD |
| US20130217789A1 (en) | 2010-09-03 | 2013-08-22 | North Carolina Central University | Biodegradable liquogel and ph sensitive nanocarriers |
| ES2385239B1 (es) | 2010-09-30 | 2013-06-19 | Proteos Biotech S.L.U. | Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno. |
| US20120237492A1 (en) * | 2011-02-18 | 2012-09-20 | Kythera Biopharmaceuticals, Inc. | Treatment of submental fat |
| US10119131B2 (en) | 2011-03-16 | 2018-11-06 | Biospecifics Technologies Corp. | Compositions and methods for producing clostridial collagenases |
| TWI461214B (zh) | 2011-06-13 | 2014-11-21 | Univ Chang Gung | Biodegradable water-sensitive glue, a drug delivery system as a carrier thereof, and a pharmaceutical composition for the treatment and / or prevention of eye diseases |
| US9333005B2 (en) * | 2011-10-17 | 2016-05-10 | Sound Surgical Technologies Llc | Ultrasonic probe for treating cellulite |
| EP3581199B1 (en) * | 2011-10-21 | 2023-05-31 | Endo Global Ventures | Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy |
| CA2861033C (en) | 2012-01-12 | 2017-07-25 | Auxilium International Holdings, Inc. | Clostridium histolyticum enzymes and methods for the use thereof |
| JP2015506247A (ja) * | 2012-01-27 | 2015-03-02 | ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 皺重症度を測定するための方法及び評価スケール |
| JP6049862B2 (ja) * | 2012-09-07 | 2016-12-21 | 株式会社 資生堂 | フィブリン３及び／又はサルコグリカンγを指標としたセルライトの評価方法及びセルライト効果薬剤の評価方法 |
| US20160000890A1 (en) | 2013-03-15 | 2016-01-07 | Biospecifics Technologies Corp. | Thermosensitive hydrogel collagenase formulations |
| KR102267689B1 (ko) * | 2013-03-15 | 2021-06-22 | 마리 케이 인코포레이티드 | 화장품 조성물들 및 이의 용도 |
| EP2968484B1 (en) | 2013-03-15 | 2020-11-25 | BioSpecifics Technologies Corporation | Treatment method and product for uterine fibroids using purified collagenase |
| CN103751102A (zh) | 2014-01-15 | 2014-04-30 | 上海交通大学 | 一种胶原酶温敏水凝胶及其制备方法和应用 |
| KR102146667B1 (ko) * | 2014-06-27 | 2020-08-21 | (주)메디톡스 | 지방 감소를 위한 담즙산 및 염의 방법 및 조성물 |
| CA3013776A1 (en) | 2016-02-08 | 2017-08-17 | OutcomeMD, Inc. | Determining a wellness, improvement, or effectiveness score |
| EP3532008B1 (en) * | 2016-10-28 | 2021-08-11 | Merz Pharma GmbH & Co. KGaA | The cosmetic treatment of cellulite |
| KR20230003601A (ko) | 2017-03-01 | 2023-01-06 | 엔도 벤쳐즈 리미티드 | 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법 |
| CN118325876A (zh) | 2017-03-28 | 2024-07-12 | 恩多风投有限公司 | 生产胶原酶的改进方法 |
-
2018
- 2018-03-01 KR KR1020227043541A patent/KR20230003601A/ko not_active Ceased
- 2018-03-01 EP EP25170305.4A patent/EP4591945A2/en active Pending
- 2018-03-01 AU AU2018226820A patent/AU2018226820B2/en active Active
- 2018-03-01 ES ES18713447T patent/ES3036011T3/es active Active
- 2018-03-01 WO PCT/US2018/020551 patent/WO2018160905A1/en not_active Ceased
- 2018-03-01 US US15/909,991 patent/US11123280B2/en active Active
- 2018-03-01 KR KR1020257003373A patent/KR20250021648A/ko active Pending
- 2018-03-01 PT PT187134473T patent/PT3589204T/pt unknown
- 2018-03-01 BR BR112019018277-2A patent/BR112019018277A2/pt active Search and Examination
- 2018-03-01 KR KR1020197028341A patent/KR102610801B1/ko active Active
- 2018-03-01 HU HUE18713447A patent/HUE072115T2/hu unknown
- 2018-03-01 CN CN201880026828.0A patent/CN110545722B/zh active Active
- 2018-03-01 EP EP18713447.3A patent/EP3589204B1/en active Active
- 2018-03-01 JP JP2019568589A patent/JP7558654B2/ja active Active
- 2018-03-01 FI FIEP18713447.3T patent/FI3589204T3/fi active
- 2018-03-01 DK DK18713447.3T patent/DK3589204T3/da active
- 2018-03-01 PL PL18713447.3T patent/PL3589204T3/pl unknown
- 2018-03-01 CN CN202211596739.4A patent/CN115969318A/zh active Pending
- 2018-03-01 IL IL301796A patent/IL301796A/en unknown
- 2018-03-01 NZ NZ756787A patent/NZ756787A/en unknown
- 2018-03-01 CA CA3055041A patent/CA3055041A1/en active Pending
-
2019
- 2019-08-28 IL IL26898519A patent/IL268985A/en unknown
- 2019-09-02 MX MX2023008072A patent/MX2023008072A/es unknown
- 2019-09-02 MX MX2023015506A patent/MX2023015506A/es unknown
-
2021
- 2021-08-30 US US17/461,481 patent/US11813347B2/en active Active
-
2022
- 2022-11-15 AU AU2022271390A patent/AU2022271390B2/en active Active
-
2023
- 2023-06-07 JP JP2023094087A patent/JP2023120246A/ja active Pending
- 2023-10-09 US US18/482,998 patent/US12403081B2/en active Active
-
2024
- 2024-03-04 AU AU2024201429A patent/AU2024201429B2/en active Active
-
2025
- 2025-07-23 AU AU2025206433A patent/AU2025206433A1/en active Pending
- 2025-08-04 US US19/289,348 patent/US20250352450A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12403081B2 (en) | Method of assessing and treating cellulite | |
| Desmeules et al. | The efficacy of therapeutic ultrasound for rotator cuff tendinopathy: A systematic review and meta-analysis | |
| Makharita et al. | Ultrasound-guided pulsed radiofrequency in the management of thoracic postherpetic neuralgia: a randomized, double-blinded, controlled trial | |
| Jones et al. | Pain education with therapeutic exercise in chronic nonspecific low back pain rehabilitation: a critically appraised topic | |
| Ahramiyanpour et al. | Carboxytherapy in dermatology: A systematic review | |
| Ng et al. | Use of micro botulinum toxin for a face-lifting effect: a systematic review | |
| Guida et al. | Hyperdiluted calcium hydroxylapatite for skin laxity and cellulite of the skin above the knee: a pilot study | |
| Avendaño-Coy et al. | Capacitive resistive monopolar radiofrequency at 448 kHz plus exercising versus exercising alone for subacromial pain: A sham-controlled randomized clinical trial | |
| Boczarska-Jedynak | Experience of treatment of chronic migraine with botulinum toxin type A among aesthetic medicine professionals in Poland | |
| Krauß et al. | Efficacy of electrical stimulation of the zygomaticus muscle in complete facial paralysis: evidence from facial grading and automated image analysis | |
| Hong et al. | The Effect of Diluted Deoxycholic Acid on Arm Fat Reduction: Evaluation of Its Potential in Minimally Invasive Fat Loss Treatment | |
| Marin et al. | A double perspective on botulinum toxin in Romania used for aesthetic clinical applications | |
| NZ796433A (en) | Apparatus and method for assessing and treating cellulite | |
| HK40089867A (zh) | 用於评估和治疗橘皮组织的装置和方法 | |
| HK40019032A (en) | Apparatus and method for assessing and treating cellulite | |
| HK40019032B (en) | Apparatus and method for assessing and treating cellulite | |
| Saito et al. | Bumpy Patches: Analgesic Effects of Particle Pressure in Sports Injury Treatment | |
| Lin | To investigate the effects of Long's Manipulation (LM) for patient with chronic mechanical neck pain: a randomized control trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority |
Free format text: PERDA DAS PRIORIDADES REQUERIDAS US 62/485,705 DE 14.04.2017 E US 62/465,622 DE 01.03.2017, POIS POSSUEM DEPOSITANTE DIFERENTE DO INFORMADO NA ENTRADA NA FASE NACIONAL E SUAS RESPECTIVAS CESSOES NAO FORAM APRESENTADAS, MOTIVO PELO QUAL SERA DADA PERDA DESTAS PRIORIDADES, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: VIDE PARECER |
|
| B15V | Prolongation of time limit allowed |
Free format text: VIDE PARECER |
|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: VIDE PARECER |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |